Standard BioTools Gross Margin 2010-2024 | LAB
Current and historical gross margin for Standard BioTools (LAB) over the last 10 years. The current gross profit margin for Standard BioTools as of September 30, 2024 is %.
| Standard BioTools Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2024-09-30 |
$0.16B |
$0.08B |
48.08% |
| 2024-06-30 |
$0.14B |
$0.06B |
46.32% |
| 2024-03-31 |
$0.13B |
$0.06B |
48.82% |
| 2023-12-31 |
$0.11B |
$0.05B |
47.17% |
| 2023-09-30 |
$0.11B |
$0.05B |
45.71% |
| 2023-06-30 |
$0.11B |
$0.05B |
43.40% |
| 2023-03-31 |
$0.10B |
$0.04B |
37.11% |
| 2022-12-31 |
$0.10B |
$0.04B |
36.36% |
| 2022-09-30 |
$0.11B |
$0.05B |
40.91% |
| 2022-06-30 |
$0.11B |
$0.05B |
44.25% |
| 2022-03-31 |
$0.13B |
$0.06B |
49.60% |
| 2021-12-31 |
$0.13B |
$0.07B |
52.67% |
| 2021-09-30 |
$0.14B |
$0.08B |
54.35% |
| 2021-06-30 |
$0.15B |
$0.09B |
57.72% |
| 2021-03-31 |
$0.14B |
$0.09B |
59.03% |
| 2020-12-31 |
$0.14B |
$0.08B |
58.99% |
| 2020-09-30 |
$0.13B |
$0.07B |
58.73% |
| 2020-06-30 |
$0.11B |
$0.06B |
56.25% |
| 2020-03-31 |
$0.11B |
$0.06B |
55.26% |
| 2019-12-31 |
$0.12B |
$0.06B |
55.17% |
| 2019-09-30 |
$0.12B |
$0.07B |
56.03% |
| 2019-06-30 |
$0.12B |
$0.07B |
56.30% |
| 2019-03-31 |
$0.12B |
$0.07B |
56.41% |
| 2018-12-31 |
$0.11B |
$0.06B |
55.36% |
| 2018-09-30 |
$0.11B |
$0.06B |
52.78% |
| 2018-06-30 |
$0.10B |
$0.05B |
50.96% |
| 2018-03-31 |
$0.10B |
$0.05B |
50.00% |
| 2017-12-31 |
$0.10B |
$0.05B |
50.49% |
| 2017-09-30 |
$0.10B |
$0.05B |
52.00% |
| 2017-06-30 |
$0.10B |
$0.05B |
53.61% |
| 2017-03-31 |
$0.10B |
$0.06B |
55.45% |
| 2016-12-31 |
$0.10B |
$0.06B |
56.73% |
| 2016-09-30 |
$0.11B |
$0.06B |
57.27% |
| 2016-06-30 |
$0.12B |
$0.07B |
58.12% |
| 2016-03-31 |
$0.12B |
$0.07B |
58.47% |
| 2015-12-31 |
$0.12B |
$0.07B |
58.62% |
| 2015-09-30 |
$0.12B |
$0.07B |
60.17% |
| 2015-06-30 |
$0.12B |
$0.07B |
60.50% |
| 2015-03-31 |
$0.12B |
$0.07B |
61.86% |
| 2014-12-31 |
$0.12B |
$0.07B |
63.25% |
| 2014-09-30 |
$0.11B |
$0.07B |
64.76% |
| 2014-06-30 |
$0.09B |
$0.06B |
67.74% |
| 2014-03-31 |
$0.08B |
$0.06B |
70.73% |
| 2013-12-31 |
$0.07B |
$0.05B |
71.83% |
| 2013-09-30 |
$0.07B |
$0.05B |
71.21% |
| 2013-06-30 |
$0.06B |
$0.04B |
70.49% |
| 2013-03-31 |
$0.06B |
$0.04B |
68.42% |
| 2012-12-31 |
$0.05B |
$0.04B |
67.92% |
| 2012-09-30 |
$0.05B |
$0.03B |
68.00% |
| 2012-06-30 |
$0.05B |
$0.03B |
66.67% |
| 2012-03-31 |
$0.05B |
$0.03B |
67.39% |
| 2011-12-31 |
$0.04B |
$0.03B |
68.18% |
| 2011-09-30 |
$0.04B |
$0.03B |
68.29% |
| 2011-06-30 |
$0.04B |
$0.03B |
71.05% |
| 2011-03-31 |
$0.04B |
$0.02B |
68.57% |
| 2010-12-31 |
$0.03B |
$0.02B |
66.67% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Information Systems |
$0.529B |
$0.106B |
|
Standard BioTools Inc. is a solution provider in health and disease using its proprietary mass cytometry and microfluidics technologies. It serves academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories. Standard BioTools Inc., formerly known as Fluidigm Corporation, is based in SOUTH SAN FRANCISCO, Calif.
|
